Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Rose Wangen, Dixie Lewis, RN,BA, JoAnn Knox, Martin Schroeder, Martin Felices, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136398

Published: 2020

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia

Upasana Sunil Arvindam, MSc, BSc, Paulien van Hauten, MSc-MD, Caroline Hallstrom, BS, Daniel A. Vallera, PhD, Harry Dolstra, PhD, Jeffrey S. Miller, MD, Martin Felices, PhD

Blood (2018) 132 (Supplement 1): 1454.

https://doi.org/10.1182/blood-2018-99-117150

Published: 2018

Journal Articles

64 cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment

Srideshikan Sargur Madabushi, PhD, Darren Zuro, Jamison Brooks, B.S, Bijender Kumar, PhD, Liliana E Parra, Marvin Orellana, B.S, Indu Nair, PhD, Junie Chea, Kofi Poku, PharmD, Ching-Cheng Chen, PhD, James Sanchez, PhD, John E. Shively, Daniel A. Vallera, PhD, Jeffrey Wong, MD, Anthony S. Stein, MD, David Colcher, PhD, Paul Yazaki, PhD, Susanta Hui, PhD, DABR.

Blood (2018) 132 (Supplement 1): 2747.

https://doi.org/10.1182/blood-2018-99-117878

Published: 2018

Journal Articles

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Martin Felices, PhD, Craig E. Eckfeldt, MD PhD, Todd R Lenvik, Behiye Kodal, Alexander J. Lenvik, Laura Bendzick, Caitlin Ryan, Melissa A. Geller, Sarah Cooley, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 4465.

https://doi.org/10.1182/blood.V130.Suppl_1.4465.4465

Published: 2017

Journal Articles

A Novel CD16xCD33 Bispecific Killer Cell Engager (BiKE) Mediates a Double Hit For Natural Killer (NK) Cells To Target CD33 + Myelodysplastic Syndrome (MDS) Cells and Myeloid Derived Suppressor Cells (MDSCs) At All Disease Stages

Michelle K. Gleason, PhD, Julie A. Ross, PhD, Troy C. Lund, MD/PhD, Michael R. Verneris, MD, Andres Wiernik, MD, Erica D. Warlick, MD, Stephen Spellman, MBS, Michael D. Haagenson, MS, Alexander J. Lenvik, Mark R. Litzow, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2013) 122 (21): 385.

https://doi.org/10.1182/blood.V122.21.385.385

Published: 2013

Journal Articles

Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 × CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)

Andres Wiernik, MD, Bree Foley, PhD, Bin Zhang, Michael R. Verneris, MD, Erica Warlick, MD, Julie A. Ross, PhD, Louis M. Weiner, MD, Daniel J. Weisdorf, MD, Daniel A Vallera, PhD, Jeffrey S. Miller, MD

Blood (2012) 120 (21): 256.

https://doi.org/10.1182/blood.V120.21.256.256

Published: 2012

Journal Articles

Treg Depletion with Interleukin-2-Diphteriatoxin (IL-2DT) Is Sufficient to Induce Tumor Clearance in Acute Myeloid Leukemia (AML)

Christoph Bucher, MD, Johanna Zhou, PhD, Heidi Mondale, PhD, Meghan Johnson, Luna Liu, Christine Vogtenhuber, PhD, Chris Lees, Yoichiro Iwakura, PhD, Daniel A Vallera, PhD, Brenda Weigel, MD, MSc, Bruce R. Blazar, MD

Blood (2008) 112 (11): 2954.

https://doi.org/10.1182/blood.V112.11.2954.2954

Published: 2008

NARROW

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia

64 cu-DOTA-Anti-CD33 PET-CT Imaging for Acute Myeloid Leukemia and Image-Guided Treatment

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

A Novel CD16xCD33 Bispecific Killer Cell Engager (BiKE) Mediates a Double Hit For Natural Killer (NK) Cells To Target CD33 + Myelodysplastic Syndrome (MDS) Cells and Myeloid Derived Suppressor Cells (MDSCs) At All Disease Stages

Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 × CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)

Treg Depletion with Interleukin-2-Diphteriatoxin (IL-2DT) Is Sufficient to Induce Tumor Clearance in Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only